Drug Developed at UM Moves to Cancer Patient Trials
MISSOULA – A compound discovered by the University of Montana Center for Translational Medicine has started Phase I clinical trials with cancer patients. The center’s partner in the effort is Inimmune Corp., a Missoula-based biotechnology company. Jay Evans, a UM researcher and director of the center, said reaching human clinical trials is a milestone for Read More…